Premium
Biologically active TGF‐β 1 is increased in cerebrospinal fluid while it is reduced in serum in multiple sclerosis patients
Author(s) -
Rollnik J. D.,
Sindern E.,
Schweppe C.,
Malin J. P.
Publication year - 1997
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1997.tb00248.x
Subject(s) - cerebrospinal fluid , multiple sclerosis , medicine , transforming growth factor , pathology , immunology
Objectives ‐ The polypeptide transforming growth factor‐β 1 (TGF‐β 1 ) is a product of activated monocytes, among other inflammatory cells, and it affects immune responsiveness, cellular growth and differentiation. TGF‐β 1 has potent T‐cell inhibiting activities. It may play an important role in limiting autoimmune inflammation. We were interested about levels of biologically active and total TGF‐β 1 in serum and CSF in patients suffering from multiple sclerosis. Subjects and methods ‐ We measured biologically active and total TGF‐β 1 in serum and CSF using ELIS A‐technique in 64 MS patients with 57 during acute exacerbation of MS and 7 in remission (primary‐relapsing: n =59; primary‐progressive: n = 5), 20 healthy subjects, and 21 patients with other non‐inflammatory neurological diseases (OND). Results ‐ Biologically active TGF‐β 1 in serum was reduced in MS patients compared to controls, on the other hand total TGF‐β 1 was elevated in CSF compared to patients with OND. Biologically active TGF‐β 1 in CSF correlated positively with the duration of the acute relapse in patients with primary‐relapsing MS. The more relapses the patients had the higher was biologically active TGF‐β 1 in CSF. Total TGF‐β 1 in CSF correlated with macrophages in CSF and albumin quotient. Conclusion ‐ We found that an elevated level of biologically active TGF‐β 1 in CSF might be useful as an indicator of disease limitation while active TGF‐β 1 in serum is reduced in multiple sclerosis. Measuring TGF‐β 1 in body fluids by ELISA techniques produces valid results and might be used for further studies focusing on the role of this cytokine in MS.